An evidence-based patient guide to the Prodromos Stem Cell Institute — what it offers, what research shows, safety considerations, and how to evaluate your options.
The Prodromos Stem Cell Institute was founded by Dr. Chadwick Prodromos, an orthopaedic surgeon with a background in sports medicine and ACL reconstruction. The clinic has positioned itself as a provider of stem cell treatments for orthopaedic conditions — including knee osteoarthritis, ACL injuries, and cartilage damage — as well as for neurological and systemic conditions in some cases.
Based on publicly available materials from the clinic, the Prodromos Stem Cell Institute has focused most of its clinical activity on musculoskeletal conditions — particularly knee osteoarthritis, partial ligament tears, and rotator cuff injuries. There are also references to treatment for neurological conditions, including multiple sclerosis and ALS, though the evidence base for MSC therapy in these conditions differs substantially from orthopaedic indications.
MSC therapy has been studied in clinical settings for over 15 years. The research base is real — thousands of patients have been enrolled in published trials covering graft-versus-host disease, Crohn's disease, cardiovascular repair, multiple sclerosis, and orthopaedic conditions. This track record informs what is now understood about safety and dosing.
For knee osteoarthritis specifically, a 2021 systematic review of randomised controlled trials found that intra-articular MSC injections produced statistically significant improvements in pain and physical function scores compared to placebo or hyaluronic acid at 6–12 months. Effect sizes were moderate. Cartilage regeneration on imaging was inconsistent across studies — some showed modest structural improvement, others showed no change. The pain-modulating and anti-inflammatory effects appear more consistent than any structural cartilage regrowth.
For MS and ALS, phase I trials have generally confirmed acceptable short-term safety profiles for intrathecal or intravenous MSC administration. Some patients in early trials reported stabilisation of disease progression or modest functional gains — but these are small, often uncontrolled studies. Phase II data is still accumulating. No neurological MSC treatment has been approved as a standard therapy by the FDA, EMA, or comparable regulatory bodies as of 2026.
Several claims made in the private stem cell clinic space — including by some US-linked offshore providers — exceed what current evidence supports. Patients should be aware of the following gaps.
This comparison is not meant to dismiss the Prodromos Institute outright. It is meant to show what questions patients should be asking of any provider — and what a regulated framework looks like by contrast. The offshore-US model and the Istanbul clinic model are both legal. But they represent different levels of institutional oversight, quality documentation, and follow-up structure.
This is one of the most common patient concerns — and it deserves a direct answer. Seeking stem cell therapy in another country is not illegal for patients from the US, UK, Australia, or most other countries. You are not breaking any law by travelling abroad for medical care.
Candidacy for stem cell therapy — whether at the Prodromos Institute, our clinic in Istanbul, or any provider — should always be determined by individual clinical assessment. There is no universal eligibility checklist. But there are patterns.
The emerging regulatory landscape for cell therapies is moving quickly. As Prof. Dr. Serdar Kabataş, MD, PhD (C) has noted in clinical commentary, the FDA's approval of Tregzi — a regulatory-T-cell therapy for prevention of acute graft-versus-host disease after allogeneic stem cell transplantation — signals that regulators are becoming more sophisticated in how they evaluate cell-based products. It is a step that increases the credibility of the broader field, while also reinforcing that the approval bar is high and clinically specific. That is the right direction. Patients evaluating private clinics should hold those clinics to a similar standard of documentation and transparency.
Before committing to any clinic, ask these questions directly. A responsible provider will welcome them. Evasive or vague answers are a warning sign.
For patients who have researched multiple providers and want to understand a regulated alternative, here is what our care pathway looks like.
No medical procedure is without risk. That includes carefully conducted stem cell therapy. Patients deserve an honest account.
This matters — and it is often the area where private clinics fall short of responsible communication. Here is what honest outcome framing looks like for common indications.
That is ultimately a decision for you and your medical team. What we can say is that the right answer to that question should come from documented evidence, transparency about cell processing, clear regulatory standing, and honest outcome tracking — not from marketing copy or testimonials alone.
The Prodromos Stem Cell Institute is a US-based private clinic founded by orthopaedic surgeon Dr. Chadwick Prodromos, offering regenerative cell therapies primarily for orthopaedic conditions. Some procedures are conducted offshore — notably in the Cayman Islands — to operate outside the FDA's IND biologics pathway. It is a legal model, but it sits outside routine FDA oversight. Patients should ask specifically about cell source, processing standards, and trial registration before proceeding.
Safety depends heavily on cell source, preparation quality, regulatory oversight of the facility, patient selection, and follow-up structure. A GMP-processed, thoroughly screened allogeneic MSC preparation administered by an experienced physician at a regulated clinic carries a very different risk profile than an uncharacterised cell product offered without documented quality testing. The short answer: quality and regulation matter far more than the phrase 'stem cell therapy' itself.
In the United States, most MSC-based therapies require an Investigational New Drug application from the FDA before they can be offered outside a registered clinical trial. Some clinics have chosen to conduct procedures in offshore jurisdictions — such as the Cayman Islands or certain Central American countries — where that requirement does not apply. This is legal but means reduced regulatory oversight. Patients considering this model should understand what oversight is absent, not just that the procedure is available.
Intra-articular MSC therapy for knee osteoarthritis is one of the better-evidenced applications in regenerative medicine. Multiple controlled trials have reported moderate improvements in pain and function at 6–12 months. The effect on structural cartilage is less consistent — anti-inflammatory and pain-modulating mechanisms appear more reliable than actual cartilage regrowth. Not every patient responds, and the therapy works best earlier in the disease course rather than at end-stage joint destruction.
Ask about cell source and whether it is autologous or allogeneic. Ask about GMP processing and sterility testing. Ask whether the protocol is registered on ClinicalTrials.gov. Ask what regulatory body oversees the procedure. Ask for documented outcome data — not just testimonials. Ask what the follow-up structure is. A clinic that cannot or will not answer these questions clearly is one to approach with caution.
For patients from the US, UK, Australia, and most other countries — yes, it is legal to travel abroad and receive medical treatment, including stem cell therapy, in a country where it is offered under that country's regulatory framework. This does not mean the treatment is approved in your home country, or that your home country's health insurance will reimburse it. The two frameworks are separate. What matters is that the destination clinic operates under a documented, accountable medical regulation — not in a regulatory vacuum.
Most international patients spend 3–7 days in Istanbul. The first day or two covers consultation and baseline assessment. The treatment session itself is outpatient and typically takes 1–2 hours. The remaining days allow for monitoring and initial follow-up before travel. Ongoing follow-up at 1, 3, and 6 months is conducted remotely, with our coordinators liaising with your local physician where needed.
If you have been researching the Prodromos Stem Cell Institute or other providers, you are asking the right questions. The most responsible next step is not choosing a clinic based on a website — it is having your case reviewed by a physician who can assess your diagnosis, your current health status, your medication list, and your realistic candidacy.
The Prodromos Stem Cell Institute: What Patients Should Know Before Deciding